Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms
OBJECTIVE: The purpose of this report was to determine 1) the effects of chronic haloperidol treatment on cerebral metabolism in schizophrenic patients, 2) the relation between negative symptoms and haloperidol-induced regional changes in cerebral glucose utilization, and 3) the relation between metabolic change and clinical antipsychotic effect.
METHOD: Cerebral glucose utilization, as determined by position emission tomography (PET), was studied in 18 male schizophrenic subjects before and after chronic treatment with haloperidol at a standardized plasma level.
RESULTS: Overall, haloperidol caused a widespread decrease in absolute cerebral glucose metabolism. The cerebral metabolic response to haloperidol was blunted in patients with high pretreatment negative symptom scores.
CONCLUSIONS: Taken together with the results from a previously reported PET study of the effects of an acute amphetamine challenge (in which 14 of the current subjects participated), these data suggest that the negative symptom complex is associated with diminished cerebral response to change in dopaminergic activity. This deficit cannot be solely accounted for by structural differences.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1996 |
|---|---|
| Erschienen: |
1996 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
The American journal of psychiatry - 153(1996), 3 vom: 29. März, Seite 346-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wolkin, A [VerfasserIn] |
|---|
| Themen: |
Amphetamines |
|---|
| Anmerkungen: |
Date Completed 24.05.1996 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM085849073 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM085849073 | ||
| 003 | DE-627 | ||
| 005 | 20231222064317.0 | ||
| 007 | tu | ||
| 008 | 231222s1996 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0286.xml |
| 035 | |a (DE-627)NLM085849073 | ||
| 035 | |a (NLM)8610821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wolkin, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms |
| 264 | 1 | |c 1996 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.1996 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: The purpose of this report was to determine 1) the effects of chronic haloperidol treatment on cerebral metabolism in schizophrenic patients, 2) the relation between negative symptoms and haloperidol-induced regional changes in cerebral glucose utilization, and 3) the relation between metabolic change and clinical antipsychotic effect | ||
| 520 | |a METHOD: Cerebral glucose utilization, as determined by position emission tomography (PET), was studied in 18 male schizophrenic subjects before and after chronic treatment with haloperidol at a standardized plasma level | ||
| 520 | |a RESULTS: Overall, haloperidol caused a widespread decrease in absolute cerebral glucose metabolism. The cerebral metabolic response to haloperidol was blunted in patients with high pretreatment negative symptom scores | ||
| 520 | |a CONCLUSIONS: Taken together with the results from a previously reported PET study of the effects of an acute amphetamine challenge (in which 14 of the current subjects participated), these data suggest that the negative symptom complex is associated with diminished cerebral response to change in dopaminergic activity. This deficit cannot be solely accounted for by structural differences | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Amphetamines |2 NLM | |
| 650 | 7 | |a Receptors, Dopamine |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Haloperidol |2 NLM | |
| 650 | 7 | |a J6292F8L3D |2 NLM | |
| 700 | 1 | |a Sanfilipo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Duncan, E |e verfasserin |4 aut | |
| 700 | 1 | |a Angrist, B |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, T B |e verfasserin |4 aut | |
| 700 | 1 | |a Brodie, J D |e verfasserin |4 aut | |
| 700 | 1 | |a Laska, E |e verfasserin |4 aut | |
| 700 | 1 | |a Rotrosen, J P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of psychiatry |d 1945 |g 153(1996), 3 vom: 29. März, Seite 346-54 |w (DE-627)NLM000012440 |x 1535-7228 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:1996 |g number:3 |g day:29 |g month:03 |g pages:346-54 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 1996 |e 3 |b 29 |c 03 |h 346-54 | ||